Canada Health Alliance

See this post by Craig Kelly. .. in Australia AND ANOTHER : New Study, Ivermectin works again. Double-blind randomised controlled study finds Ivermectin reduced ICU admissions by 83% (P <0.001) Its time that those involved in denying sick and/or dying covid patients access to Ivermectin were arrested and charged with criminal negligence and crimes against humanity. And don’t expect to find the results of this just published (April 30, 2024) study reported by the ABC or our corrupted MS Media. They’s rather cover-up these fundings than admit they were wrong. And what of all the poor simpletons that were so easily propagandised, tricked into believing that Ivermectin was a horse paste ? Will they apologise for their stupidity & ignorance? brieflands.com/articles/jjhs-… Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial - Varnaseri et al., A double-blind, randomized clinical trial was conducted on 110 patients with moderate-to-severe (non-critical) confirmed COVID-19 infection. The patients were equally divided into two groups, with one group receiving ivermectin tablets (14 mg every 12 hours for three days) and the other group receiving a placebo. Results: A total of 110 patients, including 62 (56.4%) men and 48 (43.6%) women, with an average age of 53.36 ± 15.10 years, were enrolled in our double-blind, randomized clinical trial. The baseline characteristics of the two groups were similar. The findings demonstrated that ivermectin significantly reduced the need for; 😀Intensive Care Unit admission (32.7% vs. 5.5%; P < 0.001), 😀hospitalization duration (six vs. four days; P < 0.001), and 😀median time to symptom resolution period (P < 0.05) in COVID-19 patients compared to the placebo group, without any serious side effects (P > 0.05). Based on our findings, ivermectin can be important in shortening the time to resolve symptoms such as fever, shivering, myalgia, cough, dyspnea, vomiting, and diarrhea. A recently conducted case series study has shown that combination therapy with doxycycline and ivermectin can also shorten the time to resolution for some symptoms related to COVID-19 infection in mild to moderate cases These findings agree with those reported by Ahmed et al., who assessed the effects of a 5-day therapeutic regimen consisting of ivermectin on CRP and LDH levels, representing the severity of the inflammatory phase of the illness (23). In addition to its direct antiviral effect, this medication activates inhibitory pathways involved in the inflammatory process, such as TNF-alpha, interleukin-8, and LL-37. Subsequently, there is an indirect activation of interleukin-1 beta and interleukin-18, which results in a decrease in neutrophilic and eosinophilic chemotaxis and improvement in the signs and symptoms, shortening of the course of the illness, and faster resolution of abnormal laboratory findings. Moreover, no serious adverse effects of this medication have been observed among the drug arm participants. Therefore, it seems this medication should be considered as a potential treatment for COVID-19 ……"

See this post by Craig Kelly. .. in a Australia AND ANOTHER : New Study, Ivermectin works again. Double-blind randomised controlled study finds Ivermectin reduced ICU admissions by 83% (P <0.001) Its time that those involved in denying sick and/or dying covid patients access to Ivermectin were arrested and charged with criminal negligence and crimes against humanity. And don’t expect to find the results of this just published (April 30, 2024) study reported by the ABC or our corrupted MS Media. They’s rather cover-up these fundings than admit they were wrong. And what of all the poor simpletons that were so easily propagandised, tricked into believing that Ivermectin was a horse paste ? Will they apologise for their stupidity & ignorance? brieflands.com/articles/jjhs-… Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial - Varnaseri et al., A double-blind, randomized clinical trial was conducted on 110 patients with moderate-to-severe (non-critical) confirmed COVID-19 infection. The patients were equally divided into two groups, with one group receiving ivermectin tablets (14 mg every 12 hours for three days) and the other group receiving a placebo. Results: A total of 110 patients, including 62 (56.4%) men and 48 (43.6%) women, with an average age of 53.36 ± 15.10 years, were enrolled in our double-blind, randomized clinical trial. The baseline characteristics of the two groups were similar. The findings demonstrated that ivermectin significantly reduced the need for; 😀Intensive Care Unit admission (32.7% vs. 5.5%; P < 0.001), 😀hospitalization duration (six vs. four days; P < 0.001), and 😀median time to symptom resolution period (P < 0.05) in COVID-19 patients compared to the placebo group, without any serious side effects (P > 0.05). Based on our findings, ivermectin can be important in shortening the time to resolve symptoms such as fever, shivering, myalgia, cough, dyspnea, vomiting, and diarrhea. A recently conducted case series study has shown that combination therapy with doxycycline and ivermectin can also shorten the time to resolution for some symptoms related to COVID-19 infection in mild to moderate cases These findings agree with those reported by Ahmed et al., who assessed the effects of a 5-day therapeutic regimen consisting of ivermectin on CRP and LDH levels, representing the severity of the inflammatory phase of the illness (23). In addition to its direct antiviral effect, this medication activates inhibitory pathways involved in the inflammatory process, such as TNF-alpha, interleukin-8, and LL-37. Subsequently, there is an indirect activation of interleukin-1 beta and interleukin-18, which results in a decrease in neutrophilic and eosinophilic chemotaxis and improvement in the signs and symptoms, shortening of the course of the illness, and faster resolution of abnormal laboratory findings. Moreover, no serious adverse effects of this medication have been observed among the drug arm participants. Therefore, it seems this medication should be considered as a potential treatment for COVID-19 ……"